SCHEMBL30340256

SCHEMBL30340256

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCc1c[nH]cn1)C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TLR2 O60603 1/20 0.49
▸ NMT2 O60551 2/20 0.42
▸ NMT1 P30419 2/20 0.42
▸ SLC6A5 Q9Y345 1/20 0.42
▸ CTSL P07711 1/20 0.42
▸ ROCK2 O75116 4/20 0.41
▸ PRKACA P17612 2/20 0.41
▸ AKT3 Q9Y243 2/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ NPBWR1 P48145 2/20 0.40
▸ NPY5R Q15761 3/20 0.40
▸ NPY1R P25929 2/20 0.40
▸ NPY4R P50391 2/20 0.40
▸ ITGB3 P05106 1/20 0.40
▸ ITGA2B P08514 1/20 0.40
▸ FURIN P09958 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046363 0.84 TLR2 (0.64) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL30340084 0.84 TLR2 (0.64) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL3044598 0.84 NPY4R (0.47) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL30979546 0.80 TLR2 (0.58) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL29458673 0.80 TLR2 (0.59) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL28354912 0.80 TLR2 (0.59) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL30286903 0.80 TLR2 (0.59) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL10046476 0.79 TLR2 (0.70) TLR2NMT2NMT1SLC6A5CTSL
SCHEMBL24433650 0.79 MAGI3 (0.45) TLR2CTSL
SCHEMBL29941942 0.79 SLC6A5 (0.52) TLR2NMT2NMT1SLC6A5ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059231-A1 Protease inhibitors PROTINHI B.V. (NL) 2025-02-20 — — US disclosed
WO-2024200819-A1 PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS PROTINHI B.V. (NL) 2024-10-03 — — WO disclosed
EP-4408454-A1 PROTEASE INHIBITORS Protinhi B.V. (NL) 2024-08-07 — — EP disclosed
WO-2023052636-A1 PROTEASE INHIBITORS PROTINHI B.V. (NL) 2023-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059231-A1 Protease inhibitors PREP, DNPEP, TMPRSS15 TLR2 2997/4885NMT2 463/4885NMT1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback